Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes
NCT00002377 · View on ClinicalTrials.gov ↗
Study Summary
To investigate the efficacy and safety of RS-79070 when used as induction therapy in patients with newly diagnosed peripheral retinitis. To assess the effects of induction and maintenance level dosing of RS-79070 on CMV viral load, estimated by plasma CMV PCR. To assess the pharmacokinetics of ganciclovir following administration of RS-79070 in the target population.
Conditions Studied
Interventions
- DRUG Valganciclovir
- DRUG Ganciclovir
Study Locations (19)
California
- Univ of California / Irvine — Irvine
- Univ of California / San Diego / Dept of Pediatrics — La Jolla
- Univ of California / San Diego Treatment Ctr — San Diego
- Davies Med Ctr / Institute for HIV Research — San Francisco
- Kaiser Permanente Med Ctr — San Francisco
- QUEST Clinical Research — San Francisco
New York
- New York Univ Med Ctr — New York
- St Luke's - Roosevelt Hosp Ctr / Div of Infect Dis — New York
- New York Hosp - Cornell Med Ctr — New York
Quebec
- Montreal Chest Institute — Montreal
- Royal Victoria Hosp — Montreal
District of Columbia
- Dr Alan Palestine — Washington D.C.
Florida
- Univ of Miami School of Medicine — Miami
Georgia
- Emory Eye Clinic — Atlanta
Massachusetts
- New England Med Ctr — Boston
North Carolina
- Duke Univ Eye Ctr — Durham
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-01 |
| Est. Completion | 2002-12 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002377
The ClinicalTrials.gov registry entry for NCT00002377 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Hoffmann-La Roche, which has 758 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions — of which Valganciclovir is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00002377 reports 19 study locations spanning 11 distinct geographic areas — top geographies include California, New York, Quebec. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00002377 about?
NCT00002377 is a clinical study titled "A Comparison of Valganciclovir and Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes". To investigate the efficacy and safety of RS-79070 when used as induction therapy in patients with newly diagnosed peripheral retinitis. To assess the effects of induction and maintenance level dosing of RS-79070 on CMV viral load, estimated by plasma CMV PCR. To assess the pharmacokinetics of ganci...
What is the current status of trial NCT00002377?
This trial is currently completed. It is a Phase 3 study. The study started on 1997-01. Estimated completion is 2002-12.
What conditions does trial NCT00002377 study?
This clinical trial studies the following conditions: HIV Infections, Cytomegalovirus Retinitis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00002377?
The interventions under investigation include: Valganciclovir (DRUG), Ganciclovir (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00002377?
This trial is sponsored by Hoffmann-La Roche, which has 758 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00002377 being conducted?
This trial has 19 study locations across California, District of Columbia, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.